Standardizing Cannabis Products Could Redefine Medicine in the US

Posted by

Analytical Cannabis

There needs to be standards, regulations, and traceability in the cannabis industry. Such responsibility is already deeply imprinted in the botanical medicine and herbal product industries; Good Manufacturing Practices (or any GxP) are the same across industry and jurisdictional boundaries. At the state-level, there has been a proliferation of policies and laws that relax cannabidiol issues, while operators and producers are voluntarily adopting good practices. However, a national policy must be adopted or the states will take on the responsibility of regulating cannabidiol across the country. For example, at least 20 state-based programs have adopted nearly identical regulatory requirements for medical cannabis products, these regulations were derived from best practices, developed through a voluntary consensus process, which took years to complete. As these policies are promulgated, insurance companies will be more involved, offering product liability insurance, ensuring effective recall programs and accountability.

Dr Jahan Marcu, Chief Scientific Officer and Chief Auditor Americans for Safe Access and the Patient-Focused Certification Program was speaking at The Science of Cannabis 2017 Online Symposium.